"Claudia Effenberg’s Weight Loss Secret: How Diet Injections Helped Her Lose 12kg Fast"

Claudia Effenberg’s Weight Loss Journey: What We Understand About Her Use of GLP-1 Medications

German model and television personality Claudia Effenberg has sparked widespread discussion after publicly revealing she lost 12 kilograms (approximately 26 pounds) with the help of a so-called “weight loss injection.” In a recent video shared on social media, the 60-year-old former wife of football legend Stefan Effenberg shared her experience with the treatment, which has become a global phenomenon in recent years. Even as her story has drawn both praise and skepticism, it highlights the growing role of GLP-1 receptor agonists—medications originally developed for diabetes—in the weight loss industry.

Effenberg’s disclosure comes at a time when demand for these medications has surged worldwide, driven by high-profile endorsements and social media testimonials. Still, experts caution that such treatments are not a one-size-fits-all solution and should only be used under medical supervision. Below, we break down what we know about Effenberg’s case, how these medications work, and the broader implications for public health.

Who Is Claudia Effenberg?

Claudia Effenberg, born Claudia Strunz in 1965, rose to prominence in the 1990s as a model and television host in Germany. She later gained tabloid attention for her high-profile marriage to former Bayern Munich and German national team footballer Stefan Effenberg, though the couple divorced in 2009. Now 60, Effenberg remains a recognizable figure in German media, often appearing on reality TV shows and in lifestyle segments.

In a video posted on April 26, 2026, Effenberg shared that she had lost 12 kilograms using a “diet injection,” a term commonly used in German media to describe GLP-1 receptor agonists like semaglutide (sold under brand names such as Wegovy and Ozempic) and tirzepatide (Mounjaro). While she did not specify which medication she used, her story aligns with a broader trend of celebrities and public figures openly discussing their use of these drugs for weight management.

What Are GLP-1 Medications, and How Do They Work?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications initially developed to treat type 2 diabetes. They work by mimicking the effects of a naturally occurring hormone that regulates blood sugar levels and appetite. By slowing digestion and increasing feelings of fullness, these drugs can lead to significant weight loss in many patients.

The most well-known of these medications, semaglutide, was approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in 2021 under the brand name Wegovy. A higher-dose version of the same drug, Ozempic, is approved for diabetes but has been widely prescribed off-label for weight loss. Another medication, tirzepatide (Mounjaro), which targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, has shown even greater efficacy in clinical trials and was approved for weight loss under the brand name Zepbound in late 2023.

According to a 2021 study published in The Novel England Journal of Medicine, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. However, experts emphasize that these medications are not magic bullets. They require lifestyle changes, including diet and exercise, to be effective, and they come with potential side effects such as nausea, constipation, and, in rare cases, more serious complications like pancreatitis or gallbladder disease.

Read the full study in The New England Journal of Medicine

The Rise of “Weight Loss Injections” in Popular Culture

Effenberg’s revelation is part of a larger cultural shift in how weight loss is discussed and achieved. Over the past three years, GLP-1 medications have moved from medical journals to mainstream conversation, fueled by celebrity endorsements, viral social media posts, and widespread media coverage. High-profile figures such as Elon Musk, Oprah Winfrey, and Sharon Osbourne have publicly shared their experiences with these drugs, contributing to their normalization.

In Germany, the trend has been particularly pronounced. A 2025 report by the German Federal Institute for Drugs and Medical Devices (BfArM) noted a 300% increase in prescriptions for GLP-1 medications since 2021, with a significant portion of these prescriptions being written for weight loss rather than diabetes management. The report also highlighted concerns about shortages of these medications, as demand has outpaced supply in many countries.

Read the BfArM report on GLP-1 medication trends (German)

Social media has played a pivotal role in amplifying the conversation. Platforms like TikTok and Instagram are filled with before-and-after photos, personal testimonials, and even memes about the medications. While some of these posts offer genuine support and information, others have been criticized for oversimplifying the complexities of weight loss or promoting the drugs as a quick fix. The hashtag #Ozempic, for example, has over 1.2 billion views on TikTok, with users sharing everything from their weight loss journeys to humorous takes on the side effects.

Medical Experts Urge Caution

Despite the hype, medical professionals are urging caution. Dr. Matthias Blüher, a professor of endocrinology at the University of Leipzig and a leading researcher on obesity, told Deutsche Welle in a 2025 interview that while GLP-1 medications are “a game-changer for many patients,” they are not suitable for everyone. “These drugs are powerful tools, but they are not a substitute for a healthy lifestyle,” he said. “They should be prescribed by a doctor who can monitor the patient’s progress and manage any side effects.”

One of the biggest concerns among experts is the potential for misuse. Because these medications are in high demand, some patients have turned to unregulated online pharmacies or compounded versions of the drugs, which may not meet safety standards. The European Medicines Agency (EMA) has issued warnings about counterfeit versions of semaglutide and tirzepatide, which have been linked to adverse reactions in some cases.

Read the EMA’s warning on counterfeit GLP-1 medications

Another issue is the long-term sustainability of weight loss achieved with these medications. Studies have shown that many patients regain weight after stopping the drugs, particularly if they have not made lasting changes to their diet and exercise habits. This has led some experts to question whether the medications are being overprescribed or used as a temporary solution rather than part of a comprehensive treatment plan.

What Does This Mean for Public Health?

The growing popularity of GLP-1 medications raises important questions about access, affordability, and equity. In Germany, these drugs are not universally covered by health insurance when prescribed for weight loss, leaving many patients to pay out of pocket. A month’s supply of Wegovy, for example, can cost upwards of €300 (approximately $325), making it inaccessible for many who could benefit from it.

Public health advocates are also concerned about the broader implications of framing weight loss as a primarily medical issue. While obesity is a complex condition with genetic, environmental, and behavioral factors, the focus on pharmaceutical solutions risks overshadowing the importance of systemic changes, such as improving access to healthy food, promoting physical activity, and addressing socioeconomic disparities that contribute to obesity.

At the same time, the rise of these medications has sparked important conversations about weight stigma and the pressure to conform to certain body standards. Effenberg’s openness about her weight loss journey has been praised by some as a step toward destigmatizing obesity, while others argue that it reinforces the idea that thinness is the ultimate goal.

Key Takeaways

• GLP-1 medications like semaglutide and tirzepatide are FDA-approved for weight loss but were originally developed to treat type 2 diabetes. They work by regulating appetite and slowing digestion.
• Claudia Effenberg is one of many public figures to publicly discuss using these medications. Her story reflects a broader cultural shift in how weight loss is approached.
• These drugs are not a quick fix. They require medical supervision, lifestyle changes, and can have significant side effects.
• Demand has led to shortages and concerns about counterfeit medications. Patients are advised to obtain these drugs only through licensed healthcare providers.
• Long-term weight loss sustainability remains a challenge. Many patients regain weight after stopping the medications if they have not made lasting lifestyle changes.
• Access and affordability are major barriers. In many countries, these medications are not covered by insurance for weight loss, limiting their use to those who can afford them.

What Happens Next?

As the conversation around GLP-1 medications continues to evolve, several key developments are on the horizon. In the coming months, the EMA is expected to release updated guidelines on the use of these drugs for weight management, including recommendations for healthcare providers on patient selection and monitoring. Pharmaceutical companies are racing to develop next-generation weight loss medications, with several new drugs in late-stage clinical trials.

For individuals considering these medications, the most important step is to consult with a healthcare provider. Weight loss is a deeply personal journey, and what works for one person may not be suitable for another. As Effenberg’s story shows, there is no one-size-fits-all solution—but with the right information and support, it is possible to create informed decisions about health and well-being.

We seek to hear from you: Have you or someone you know used GLP-1 medications for weight loss? What was your experience? Share your thoughts in the comments below, and don’t forget to share this article with anyone who might find it helpful.